Loading clinical trials...
Loading clinical trials...
Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Conditions
Interventions
INO-4201
INO-4202
+4 more
Locations
3
United States
QPS MRA
Miami, Florida, United States
The Center for Pharmaceutical Research
Kansas City, Missouri, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
May 1, 2015
Primary Completion Date
May 24, 2018
Completion Date
May 24, 2018
Last Updated
June 28, 2019
Lead Sponsor
Inovio Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions